Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: the SARICOR Randomized Clinical Trial

The objective of this study was to investigate the efficacy and safety of early treatment with sarilumab, added to standard of care (SOC), in hospitalized adults with COVID-19. Methods included phase II, open-label, randomized, controlled clinical trial of hospitalized patients with COVID-19 pneumon...

Descripción completa

Detalles Bibliográficos
Autores principales: Merchante, Nicolás, Cárcel, Sheila, Garrido-Gracia, José Carlos, Trigo-Rodríguez, Marta, Moreno, María Ángeles Esteban, León-López, Rafael, Espíndola-Gómez, Reinaldo, Alonso, Eduardo Aguilar, García, David Vinuesa, Romero-Palacios, Alberto, Pérez-Camacho, Inés, Gutiérrez-Gutiérrez, Belén, Martínez-Marcos, Francisco Javier, Fernández-Roldán, Concepción, Pérez-Crespo, Pedro María Martínez, Caño, Alexandra Aceituno, León, Eva, Corzo, Juan E., de la Fuente, Carmen, Torre-Cisneros, Julián
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8846457/
https://www.ncbi.nlm.nih.gov/pubmed/34902262
http://dx.doi.org/10.1128/aac.02107-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8846457/
https://www.ncbi.nlm.nih.gov/pubmed/34902262
http://dx.doi.org/10.1128/aac.02107-21

Ejemplares similares